ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

LLY Eli Lilly and Company

33.02
0.53 (1.63%)
Last Updated: 19:24:29
Delayed by 15 minutes
Name Symbol Market Type
Eli Lilly and Company NEO:LLY NEO Depository Receipt
  Price Change % Change Price Bid Price Offer Price High Price Low Price Open Price Traded Last Trade
  0.53 1.63% 33.02 33.02 33.03 33.27 32.45 32.75 23,359 19:24:29

Patients Taking Cymbalta(R) Reported Reduced Pain Severity of Osteoarthritis of the Knee in New Study

13/06/2008 1:00pm

PR Newswire (US)


Eli Lilly (NEO:LLY)
Historical Stock Chart


From Jul 2019 to Jul 2024

Click Here for more Eli Lilly Charts.
Patients on Treatment Also Experienced Improved Physical Functioning INDIANAPOLIS, June 13 /PRNewswire-FirstCall/ -- New data suggest that patients with osteoarthritis pain of the knee treated with 60 mg and 120 mg Cymbalta (duloxetine HCl) once daily experienced significant pain reduction. Patients taking duloxetine reported significant pain improvement compared to placebo within the first week of treatment that lasted throughout the 13-week trial.(1) Results from the study of 231 patients were presented today at the annual congress of the European League Against Rheumatism (EULAR) in Paris, France. Duloxetine showed statistically significant improvement in pain associated with osteoarthritis of the knee according to the primary efficacy measure of mean 24-hour average pain scores. Fifty-nine percent of duloxetine-treated patients experienced a 30 percent improvement in pain compared with 45 percent of patients taking placebo. Forty-seven percent of duloxetine-treated patients experienced a 50 percent improvement in pain compared with 29 percent of placebo-treated patients. Treatment with duloxetine also was associated with improved patient outcomes compared with placebo as measured by the Patient Global Impressions of Improvement (PGI-I) and physical functioning as measured by the Western Ontario and McMaster Universities (WOMAC) physical functioning subscale. In this study, the most common adverse events (occurred at a rate of greater than or equal to 3 percent and at least twice the rate of placebo) were nausea, fatigue, somnolence, dizziness, hypertension, constipation and decreased libido. "These data are important because it's the first time duloxetine has been studied in a large, placebo-controlled trial in what's classified as an inflammatory disease state," said Amy Chappell, M.D., lead study author and medical fellow II, Eli Lilly and Company. "Although the exact mechanism of action is unknown, this study may provide important insights into the treatment of pain in the central nervous system." It is estimated that 27 million adults in the United States have osteoarthritis and the prevalence increases with age.(2) Osteoarthritis of the knee is a common type of this disorder, impacting the lives of approximately 10 million Americans.(2) Other symptoms of osteoarthritis in addition to pain include aching, stiffness and limited range of motion of the joint.(3) Additional Study Highlights: - Compared with patients receiving placebo, patients receiving duloxetine experienced significant improvement in symptom severity associated with osteoarthritis pain of the knee, including: * Significantly greater reduction in Brief Pain Inventory (BPI) average pain severity (p

1 Year Eli Lilly Chart

1 Year Eli Lilly Chart

1 Month Eli Lilly Chart

1 Month Eli Lilly Chart

Your Recent History

Delayed Upgrade Clock